Pacific Biosciences, a US-based gene sequencing company, has extended its series F funding to $109m, having last month raised $50m from Nasdaq-listed peer Gen-Probe as part of the round.
Pacific Biosciences has raised $370m in total. Alongside Gen-Probe, its funders include crop company Monsanto, chip company Intel Capital and UK medical foundation Wellcome Trust.
The company’s venture capital and asset management backers are Sutter Hill Ventures, Deerfield Management, Morgan Stanley, Redmile Group, T Rowe Price, Mohr Davidow Ventures, Kleiner Perkins Caufield and Byers, Alloy Ventures, Maverick Capital, AllianceBernstein, DAG Ventures, Teachers’ Private Capital and Blackstone Cleantech Venture Partners.